A 26-year-old woman with lymphoangioleiomyomatosis (LAM) 
Introduction

Angiomyolipoma (AML) is a rare tumor that originates in the kidney and liver and is generally benign. This tumor is frequently found in patients with tuberous sclerosis complex (TSC) as well as in those with sporadic pulmonary lymphangioleiomyomatosis (LAM) (1, 2). TSC1 and TSC2 gene mutations are involved in the development of TSC (3). TSC 2 gene mutation and persistent activation of the mammalian target of the rapamycin (mTOR) pathway are involved in the pathogenesis of sporadic LAM and AML (4). Therefore, it is plausible that rapamycin/sirolimus inhibits AML growth. A recent clinical trial study confirmed that AML regresses in response to sirolimus therapy (5). AML is typically characterized by tortuous, thick-walled blood vessels; phenotypic smooth muscle cells; and adipose cells in varying proportions
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F i g u r e 1 . P r i ma r y t u mo r o f t h e r i g h t k i d n e y : Ho r i z o n t a l v i e w o f t h e a b d o mi n a l e n h a n c e d CT s c a n ( A) a n d t h e s a g i t t a l v i e w o f t h e ma g n e t i c r e s o n a n c e i ma g i n g ( MRI ) s c a n ( B ) . S p i n d l e -
Case Report
In July 2004, a 26-year-old woman was admitted to our hospital for elective surgical resection of a giant tumor in the right kidney (Fig. 1) (Fig. 2b, c) . Immunohistochemical analyses revealed that the tumor cells were HMB-45 positive (Fig. 2d) , while they were negative for epithelial membrane antigen (EMA), anion exchanger 1 (AE1)/AE3, vimentin, desmin, smooth muscle actin (SMA), S100, chromogranin A, and synaptophysin. Therefore, a pathological diagnosis of epithelioid AML was made.
One month after the resection of the liver tumors, a chest CT scan showed multiple metastatic tumors in the lung (Fig. 3a, b) ; however, it was not possible to perform surgical resection. Based on previous reports (9, 10) (Fig. 3c, d ). The tumor sizes, which were measured on CT, indicated that their growth rate was not affected by si- T a b l e 1 . L a b o r a t o r y F i n d i n g s a t F i r s t Ad mi s s i o 
F i g u r e 2 . Mu l t i p l e l i v e r t u mo r s i n t h e l i v e r : Ab d o mi n a l e n h a n c e d CT s c a n s h o ws mu l t i p l e l i v e r t u mo r s ( A) . E p i t h e l i o i d c e l l s wi t h e o s i n o p h i l i c c y t o p l a s m a n d p l e i o mo r p h i c n u c l e i a r e s e e n , i n d i c a ti n g e p i t h e l i o i d AML ( He ma t o x y l i n a n d E o s i n s t a i n i n g ) ( B , 1 0 0 × ; C, 2 0 0 × ) . T h e e p i t h e l i o i d c e l l s we r e HMB -4 5 p o s i t i v e ( D) .
F i g u r e 3 . Mu l t i p l e l u n g me t a s t a s e s o f t h e e p i t h e l i o i d AML : CT i ma g e s b e f o r e s i r o l i mu s t r e a tme n t ( A a n d B ) a n d a f t e r 4 mo n t h s o f t r e a t me n t ( C a n d D) . A a n d C a r e t h e i ma g e s a t t h e s a me l e v e l o f t h e mi d -l u n g f i e l d . B a n d D a r e a n o t h e r s e t o f i ma g e s a t t h e s a me l e v e l o f t h e l o we r l u n g f i e l d .
them were Ki67 positive. Previously, 5 cases of malignant transformation of AML have been reported (11) (12) (13) (14) (15) TSC2 gene mutation is involved in the pathogenesis of both conventional AML (9) and LAM (16 (18) . In addition, a previous case report showed that gefitinib, an EGFR inhibitor, is effective in the treatment of AML (10) ; however, in our case, the epithelioid AML did not respond to gefitinib. Genomic analyses revealed that there was no significant mutation in the EGFR gene in the tumor, and this was in agreement with the findings of a recent study (19) . It has been reported that estrogen regulates AML cell proliferation (20 
